--Intravenous gene delivery demonstrates efficacy in pre-clinical studies of breast cancer and head and neck cancer--
San Francisco, CA -- April 3, 2000 -- Targeted Genetics Corporation (Nasdaq: TGEN) today presented data on the company's synthetic gene delivery platform at the American Association of Cancer Research 91st Annual Meeting being held in San Francisco. Dr. Pervin Anklesaria, Senior Director of Research at Targeted Genetics, presented data indicating that the company's LPD (Lipid Polycation DNA) gene delivery system is capable of delivering genes systemically when delivered intravenously. Intravenous delivery of tgLPD-E1A, the company's second-generation cancer therapeutic, inhibited tumor growth in animal models of two different human tumors. The data were presented in an abstract titled "Systemic and Local Delivery of E1A-Cationic Lipid Complex Chemosensitizes Breast and Ovarian Cancer Cells In Vivo."
Advances in Systemic Gene Delivery Technology
In a study presented today, the LPD delivery system was used to deliver E1A, a proprietary tumor inhibitor gene, systemically to mice transplanted with human head and neck tumors. tgLPD-E1A was administered weekly beginning six days after tumor cells were transplanted into the animals. These cells express basal levels of HER-2/neu. At 13 weeks, 70 percent of the animals treated with tgLPD-E1A were tumor free, compared to only 10 percent of animals receiving either lipid alone or 5FU, and only 50 percent of animals receiving a lipoplex-E1A control.
"We have now demonstrated that intravenous delivery of tgLPD-E1A is able to inhibit tumor growth in animal models of breast and head and neck cancers," said Dr. Anklesaria. "These data show that the LPD gene delivery system may enable the systemic delivery of therapeutic genes, an important step in the evolution of gene delivery technologies. Significantly, tgLPD-E1A was seven-fold more effective at inhib
Contact: Page Sargisson